Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Inventory (2018 - 2025)

Coherus Oncology (CHRS) has disclosed Change in Inventory for 8 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 82.74% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.1 million through Dec 2025, down 46.46% year-over-year, with the annual reading at $17.1 million for FY2025, 46.46% down from the prior year.
  • Change in Inventory hit $1.1 million in Q4 2025 for Coherus Oncology, up from -$2.5 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $23.4 million in Q3 2022 to a low of -$7.5 million in Q2 2021.
  • Historically, Change in Inventory has averaged $7.5 million across 5 years, with a median of $8.1 million in 2021.
  • Biggest five-year swings in Change in Inventory: tumbled 241.08% in 2021 and later surged 443.63% in 2022.
  • Year by year, Change in Inventory stood at $9.2 million in 2021, then rose by 6.56% to $9.8 million in 2022, then rose by 20.44% to $11.8 million in 2023, then plummeted by 45.28% to $6.5 million in 2024, then plummeted by 82.74% to $1.1 million in 2025.
  • Business Quant data shows Change in Inventory for CHRS at $1.1 million in Q4 2025, -$2.5 million in Q3 2025, and -$3.8 million in Q2 2025.